• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

    5/23/24 8:47:33 AM ET
    $BRN
    $ERAS
    $LAB
    $MGLD
    Oil & Gas Production
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BRN alert in real time by email

    The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Marygold Companies

    • The Trade: The Marygold Companies, Inc. (NYSE:MGLD) 10% owner Nicholas & Melinda Gerber Living Trust bought a total of 80,000 shares at an average price of $1.35. To acquire these shares, it cost around $107,760.
    • What's Happening: On May 13, Marygold Companies reported financial results for the three and nine months ended March 31.
    • What Marygold Companies Does: The Marygold Companies Inc is engaged in identifying and acquiring established, profitable, undervalued companies in diverse sectors, and managing the portfolio to facilitate growth and add value for all stakeholders.

    Standard BioTools

    • The Trade: Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners FO1-MSV, LP acquired a total of 600,000 shares at an average price of $2.57. To acquire these shares, it cost around $1.54 million.
    • What's Happening: On May 8, Standard BioTools posted downbeat quarterly sales.
    • What Standard BioTools Does: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster.

    Check This Out: Top 5 Industrials Stocks That May Explode This Quarter

    Erasca

    • The Trade: Erasca, Inc. (NASDAQ:ERAS) Director Alexander W. Casdin acquired a total of 80,000 shares at an average price of $2.27. The insider spent around $181,920 to buy those shares.
    • What's Happening: On May 21, Erasca announced closing of underwritten offering of common stock and full exercise of the underwriters’ option to purchase additional shares.
    • What Erasca Does: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

    Barnwell Industries

    • The Trade: Barnwell Industries, Inc. (NYSE:BRN) 10% owner Sherwood Revocable Trust acquired a total of 22,486 shares at an average price of $2.82. The insider spent around $63,329 to buy those shares.
    • What's Happening: On May 14, Barnwell Industries reported financial results for its second fiscal quarter ended March 31.
    • What Barnwell Industries Does: Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas.

    Don’t forget to check out our premarket coverage here

    Get the next $BRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRN
    $ERAS
    $LAB
    $MGLD

    CompanyDatePrice TargetRatingAnalyst
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    Erasca Inc.
    $ERAS
    1/7/2026$5.00Overweight
    Piper Sandler
    Erasca Inc.
    $ERAS
    10/16/2025$4.00Buy
    Stifel
    Erasca Inc.
    $ERAS
    9/3/2025Buy → Underperform
    BofA Securities
    Erasca Inc.
    $ERAS
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    Standard BioTools Inc.
    $LAB
    8/13/2025$1.55Buy → Hold
    TD Cowen
    Erasca Inc.
    $ERAS
    3/26/2025$5.00Outperform
    Raymond James
    Standard BioTools Inc.
    $LAB
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $BRN
    $ERAS
    $LAB
    $MGLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

    Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for

    3/12/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

    Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will

    3/10/26 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

    ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (NASDAQ:TNGX, "Tango")) to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, with Tango's PRMT5 inhibitor, vopimetostat (TNG462). "We've disclosed encoura

    3/5/26 7:01:00 AM ET
    $ERAS
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRN
    $ERAS
    $LAB
    $MGLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Erasca with a new price target

    Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

    1/7/26 9:10:17 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Erasca with a new price target

    Stifel initiated coverage of Erasca with a rating of Buy and set a new price target of $4.00

    10/16/25 8:25:25 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRN
    $ERAS
    $LAB
    $MGLD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Horowitz Joshua bought $4,655 worth of shares (4,433 units at $1.05) (SEC Form 4)

    4 - BARNWELL INDUSTRIES INC (0000010048) (Issuer)

    2/27/26 6:11:14 PM ET
    $BRN
    Oil & Gas Production
    Energy

    Chief Executive Officer Nicholas & Melinda Gerber Living Trust bought $23,175 worth of shares (25,000 units at $0.93), increasing direct ownership by 0.13% to 18,751,125 units (SEC Form 4)

    4 - Marygold Companies, Inc. (0001005101) (Issuer)

    12/12/25 12:12:16 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    12/4/25 8:59:44 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRN
    $ERAS
    $LAB
    $MGLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Egholm Michael

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    4/8/26 9:55:05 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Kim Hanjoon Alex

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    4/8/26 9:55:03 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Mackay Sean

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    4/8/26 9:55:04 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRN
    $ERAS
    $LAB
    $MGLD
    SEC Filings

    View All

    SEC Form 424B5 filed by Barnwell Industries Inc.

    424B5 - BARNWELL INDUSTRIES INC (0000010048) (Filer)

    4/9/26 5:20:52 PM ET
    $BRN
    Oil & Gas Production
    Energy

    SEC Form 144 filed by Erasca Inc.

    144 - Erasca, Inc. (0001761918) (Subject)

    4/1/26 2:19:36 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnwell Industries Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BARNWELL INDUSTRIES INC (0000010048) (Filer)

    3/27/26 6:01:04 AM ET
    $BRN
    Oil & Gas Production
    Energy

    $BRN
    $ERAS
    $LAB
    $MGLD
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Leading Proxy Advisory Firm Glass Lewis Soundly Rejects Sherwood Group's Attempt to Seize Control of Barnwell

    Glass Lewis Opposes Removal of Barnwell Board Members Ken Grossman, Josh Horowitz and Alex Kinzler Barnwell Shareholders Should Ignore and Discard Any Blue Consent Solicitation Card Shareholders Who Sent a Blue Consent Solicitation Card Can Revoke Their Vote by Sending the Company's White Card HONOLULU, Hawaii, April 29, 2025 /PRNewswire/ -- Barnwell Industries, Inc. ("Barnwell" or the "Company") (NYSE:BRN) today announced that Glass Lewis, a leading independent proxy advisory firm, has resoundingly rejected the Sherwood Group's efforts to take control of the Company and declared the removal of Barnwell directors Ken Grossman, Josh Horowitz and Alex Kinzler to be unwarranted.

    4/29/25 11:37:00 AM ET
    $BRN
    Oil & Gas Production
    Energy

    Barnwell Industries, Inc. Informs Ned Sherwood of Defective and Insufficient Director Nomination Notice and Investigation of Circumstances that May Have Triggered Shareholder Rights Plan

    Actions Continue Ned Sherwood's Long History of Disruption, Breaches of Settlement Agreements and Blatant Disregard for Established Bylaws and Shareholder Protections Board Forms Executive Committee to Protect Shareholder Interests Executive Committee Believes Sherwood's Nomination of Himself, His Friends and His Affiliates Underscores Desire to Take Control of Barnwell at Shareholders' Expense and Without Paying a Premium for Control HONOLULU, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE:BRN) ("Barnwell" or the "Company") today announced that it has informed Ned Sherwood, a shareholder who recently submitted a control slate of five nominees comprising

    2/25/25 6:00:00 AM ET
    $BRN
    Oil & Gas Production
    Energy

    $BRN
    $ERAS
    $LAB
    $MGLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Barnwell Industries Inc.

    SC 13D/A - BARNWELL INDUSTRIES INC (0000010048) (Subject)

    12/6/24 11:27:43 AM ET
    $BRN
    Oil & Gas Production
    Energy

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 4:04:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRN
    $ERAS
    $LAB
    $MGLD
    Financials

    Live finance-specific insights

    View All

    The Marygold Companies Reports Financial Results For its Second Fiscal Quarter Ended December 31, 2025

    The Marygold Companies, Inc. (the "Company") (NYSE:MGLD), a global holding firm with a focus on financial services, today reported financial results for its second fiscal quarter ended December 31, 2025. Revenue for the three months ended December 31, 2025, amounted to $7.6 million, compared with the prior year period, when revenues were $8.0 million and which also included $0.6 million from Brigadier Security Systems (2000) Ltd. ("Brigadier"), a wholly owned subsidiary that was sold in July 2025 for $2.5 million. The Company's net loss for the quarter was $0.6 million as compared with a net loss of $1.7 million for the second quarter of the prior fiscal year. The $1.1 million improvement

    2/5/26 5:00:00 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    The Marygold Companies Reports Financial Results for First Fiscal Quarter Ended September 30, 2025

    The Marygold Companies, Inc. (the "Company") (NYSE:MGLD), a global holding firm with a focus on financial services, today reported financial results for its first fiscal quarter ended September 30, 2025. Revenue for the three months ended September 30, 2025, amounted to $7.0 million, compared with $7.9 million for the same period last year. The Company also recorded a $0.5 million gain on the sale of Brigadier Securities Systems, a Canadian-based wholly owned subsidiary that was sold for $2.3 million in July 2025. The Company sustained a net loss of $0.4 million, equal to $0.01 per share, for the quarter ended September 30, 2025, as compared with a net loss of $1.6 million, or $0.04 per s

    11/7/25 4:10:00 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    Standard BioTools Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

    8/11/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials